Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure

Background. Life-time diagnostics of wild type transthyretin amyloidosis (ATTR(wt)-amyloidosis) is virtually absent, even though ATTR(wt)-amyloidosis is an underestimated cause for morbidity and mortality, particularly in the older age group. Aim. To study incidence, demographic characteristics, and morpho-functional features of ATTR(wt)-amyloidosis in patients with FC IV CHF and LV hypertrophy > 15 mm accord ing to autopsy data. Materials and methods. Postmortem reports were retrospectively analyzed for patients (n=141; 19% males, 81% females) of cardiology departments aged ≥69 with the underlying CHF syndrome. From all formalin-fixed fragments of the myocardium embedded in paraffin were prepared 5-7 mkm cuts, which were stained with Congo red (Sigma, USA) and viewed under normal and polarized light. Immunohistochemical analysis was also performed using antibodies to AA-amyloid, transthyretin, kappa and lambda-light chains of immunoglobulins. Results. Amyloid deposits were found in both old and very old persons aged 91.25±9.67, mostly in women due to shorter life span of men. In different FCs associated with LV hypertrophy, according to autopsy data amyloid deposits were observed in virtually every fifth deceased (21% of cases). The amount of myocardial amyloid deposits was generally small (56% of cases had (+) and 27% had (++) amyloid deposits); 17% of cases had considerable amyloid deposits (7% had (+++) and 10% had (++++)). The presence of amyloid deposits did not influence indexes of myocardial hypertrophy, such as ventricular septum thickness, LV posterior wall thickness, and heart mass. In the presented cases we observed focal amyloid deposition in the myocardium typical for old age-related amyloidosis; in 97% cases, amyloid was located in the interstitium, around cardiomyocytes and in 3% of cases - exclusively around blood vessels. Conclusion. ATTR (wt)-amyloidosis was detected in every fifth patient in the old and very old cohort, primarily in women (83%), and was not diagnosed during the life time. Characteristic morphological manifestations of ATTR(wt)-amyloidosis were focal amyloid deposits mostly in the myocardial interstitium.

транстиретиновый Амиоидоз дикого типа, старческий Амилоидоз, фенокопия ГКМП, хроническая сердечная недостаточность, wild-type transthyretin amyloidosis, senile amidoidosis, a phenocopy of hypertrophic cardiomyopathy, chronic heart failure

1. Authors / Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35 (39):2733-79. DOI: 10.1093/eurheartj/ehu284

2. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL et al. Heart failure due to age-related cardiac amyloid disease associatd with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2015; CIRCULATIONAHA. 115.018852. DOI:10.1161/CIRCULATIONAHA. 115.018852

3. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des. 2008;14 (30):3219-30.

4. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. The Lancet. 2016;387 (10038):2641-54. DOI:10.1016/S0140-6736 (15) 01274-X

5. Larsen BT, Mereuta OM, Dasari S, Fayyaz AU, TheisJD, VranaJA et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2016;68 (5):648-56. DOI:10.1111/his. 12793

6. Kieninger B, Eriksson M, Kandolf R, Schnabel PA, Schönland S, Kristen AV et al. Amyloid in endomyocardial biopsies. Virchows Archiv. 2010;456 (5):523-32. DOI:10.1007/s00428-010-0909-5

7. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al. Genotype and phenotype of transthyretin cardiac amyloidosis. Journal of the American College of Cardiology. 2016;68 (2):161-72. DOI:10.1016/j. jacc. 2016.03.596

8. Tanskanen M, Peuralinna T, Polvikoski T, Notkola I, Sulkava R, Hardy J et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Annals of Medicine. 2008;40 (3):232-9. DOI:10.1080/07853890701842988

9. Cornwell GG, Murdoch WL, Kyle RA., Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinico-pathologic correlation. Am J Med. 1983;75 (4):618-23

10. Гусельникова В. В., Кирик О. В., Федорова Е. А., Шавловский М. М., Гудкова А. Я., Коржевский Д. Э. Быстрый способ окраски амилоида Конго красным для световой и флюоресцентной микроскопии. Морфология. 2016;149 (2):84-8.

11. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21 (4):221-4. DOI:10.310 9/13506129.2014.964858

12. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23 (4):209-13. DOI:10.1 080/13506129.2016.1257986

13. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SDJ et al. Systemic amyloidosis in England: an epidemiological study. British Journal of Haematology. 2013;161 (4):525-32. DOI:10.1111/bjh. 12286

14. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Clinical perspective. Circulation. 2016;133 (24):2404-12. DOI:10.1161/CIRCULATIONAHA. 116.021612

15. Kristen AV, Brokbals E, aus dem Siepen F, Bauer R, Hein S, Aurich M et al. Cardiac amyloid load.Journal ofthe American College of Cardiology. 2016;68 (1):13-24. DOI:10.1016/j. jacc. 2016.04.035

16. Smith TJ, Kyle RA., Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984;59 (8):547-55.

17. Crotty TB, Li CY, Edwards WD, Suman VJ. Amyloidosis and endomyocardial biopsy: correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol. 1995;4 (1):39-42.

18. Hoyer C, Angermann CE, Knop S, Ertl G, Störk S. Kardiale amyloidose. Medizinische Klinik. 2008;103 (3):153-60. DOI:10.1007/ s00063-008-1022-2

19. Hassan W, Al-Sergani H, Mourad W, Tabbaa R. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32(2):178-84.